Private equity firms Ardian, CVC, and Verdane are considering investments in various subsegments of the women’s health market, according to PE Hub. Exellere Partners and GHO Capital Partners have agreed to sell a pathology services company to Agilent Therapeutics for $950 million, driven by momentum in the sector. Vistria has announced new appointments as part of its operations.
Interest in Women’s Health
Ardian, CVC, and Verdane have caught the eye of opportunities in women’s health subsegments, as highlighted in the report. This development reflects ongoing activity in healthcare investments by these firms, according to PE Hub.
Exit in Pathology Services
Exellere Partners and GHO Capital Partners are exiting their investment through a $950 million sale of a pathology services company to Agilent Therapeutics. This transaction underscores momentum in pathology services, as noted in the source material.
New Appointments at Vistria
Vistria has announced new appointments, adding to its team amid broader private equity activities. According to PE Hub, these changes align with the firm’s ongoing operations in the sector.
